Clinical Trial Search

Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

Influenza

Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers

Emory University Results Dec 2018 0.0% serious AE View details

Phase 2 N=100 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

Primary: 2-year Disease-free Survival — 88 Participants

Massachusetts General Hospital Results Dec 2018 20.0% serious AE View details

N/A N=3,243 Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems

Pregnancy, Newborn Health

Primary: Percentage of Subjects Delivering at a Study Site. — 99.20; 100; 99.65; 100 Percentages of subjects

Novartis Vaccines Results Dec 2018 View details

Phase 2 N=38 Sex/Gender Differences in Risk and Resilience to PTSD; Implication of Oxytocin

PTSD

Primary: Change in Amygdala Activation- Oxy Minus Placebo — -0.01; -0.02; 0.05; 0.21 percentage of BOLD signal change

Megan Moran-Santa Maria Results Dec 2018 0.0% serious AE View details

Phase 2 N=431 A Study of a New Drug Treatment for Acne

Acne Vulgaris

Primary: Change in Total Acne Lesion Counts — -26.0; -25.2; -29.4; -33.1 Lesions

Bausch Health Americas, Inc. Results Dec 2018 0.0% serious AE View details

Phase 4 N=86 Clinical Comparison of Femoral Nerve Versus Adductor Canal Block Following Anterior Ligament Reconstruction

Anterior Cruciate Ligament Injury

Primary: Quadriceps Muscle Activation as Assessed by Surface Electromyography (sEMG) — 266.5; 212.5 microvolts (uV)

The University of Texas Health Science Center… Results Dec 2018 0.0% serious AE View details

N/A N=50 Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses

Visual Acuity

Primary: Overall Fit Acceptance — 0; 0; 0; 0 Eyes

Johnson & Johnson Vision Care, Inc. Results Dec 2018 0.0% serious AE View details

N/A N=238 Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease

Peripheral Artery Disease · Amputation · Smoking

Primary: Positive Predictive Value of Digital ABI in Diagnosing PAD — 8; 2 Participants

St. Louis University Results Dec 2018 0.0% serious AE View details

Phase 2 N=294 Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Hodgkin Disease

Primary: Objective Response Rate (ORR) Based on IRRC Assessments in Cohorts A, B, and C — 65.1; 67.5; 73.0 Percentage of Particpants

Bristol-Myers Squibb Results Dec 2018 34.4% serious AE View details

Phase 3 N=135 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in HbA1c (Glycosylated Haemoglobin) — -0.643; 0.415 Percentage of HbA1c — p=<0.001

Novo Nordisk A/S Results Dec 2018 9.4% serious AE View details

Phase 2 N=10 Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

Brain Tumors With Ill-defined Margins

Primary: Extent of Resection — 97.1 percentage of tumor resected

Weill Medical College of Cornell University Results Dec 2018 10.0% serious AE View details

Phase 3 N=75 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

Urinary Tract Infection Complicated · Acute Pyelonephritis · Hospital Acquired Bacterial Pneumonia

Primary: Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success…

Rempex (a wholly owned subsidiary of Melinta… Results Dec 2018 37.3% serious AE View details

Phase 4 N=200 Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

Influenza · Healthy

Primary: Percentage of Participants With A/H1N1 Hemagglutination Inhibition (HAI) Antibody Seroconversion Rate at Day 28 — 10.0; 5.4; 23.4 Percentage of participants — p=0.006

MedImmune LLC Results Dec 2018 0.0% serious AE View details

N/A N=348 Dental Support Device in the Second Stage of Labor

Labor

Primary: Dilation Duration of Second Stage of Labor Time — 82; 90 minutes

Angela Bianco Results Dec 2018 View details

Phase 3 N=464 Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

Urinary Tract Infection Symptomatic · Acute Pyelonephritis · Urinary Tract Infection Complicated

Primary: Number of Patients With an Overall Success — 119; 97 Participants

Nabriva Therapeutics AG Results Dec 2018 2.4% serious AE View details